SCHEMBL5097131

SCHEMBL5097131

CCOC(=O)c1nn(S(=O)(=O)c2ccc3c(c2)OCCN3C)c2cc(N3CCN(C)CC3)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP9X Q93008 2/20 0.40
GHSR Q92847 1/20 0.39
GBA1 P04062 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
CYP2C9 P11712 1/20 0.37
HDAC3 O15379 2/20 0.37
HDAC4 P56524 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC7 Q8WUI4 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC10 Q969S8 2/20 0.37
HDAC11 Q96DB2 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC9 Q9UKV0 2/20 0.37
HDAC5 Q9UQL6 2/20 0.37
SCN9A Q15858 1/20 0.37
ALDH1A1 P00352 3/20 0.37
POLB P06746 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5097139 0.92 GHSR (0.39) USP9XGHSRGBA1L3MBTL1HDAC3
SCHEMBL5095045 0.84 KHK (0.47) USP9XGHSRGBA1L3MBTL1HDAC3
SCHEMBL5103473 0.82 HTR6 (0.48) CYP2C9ALDH1A1ELANERXFP1HTT
SCHEMBL14140333 0.81 USP9X (0.42) USP9XGHSRGBA1L3MBTL1ALDH1A1
SCHEMBL5095027 0.77 KHK (0.45) GHSRGBA1L3MBTL1ALDH1A1POLB
SCHEMBL5094990 0.77 KHK (0.47) GHSRGBA1L3MBTL1ALDH1A1HTT
SCHEMBL5103502 0.76 GBA1 (0.44) USP9XGHSRGBA1L3MBTL1HDAC3
SCHEMBL5097497 0.75 THRB (0.40) CYP2C9ALDH1A1POLBELANERXFP1
SCHEMBL14140641 0.73 GHSR (0.39) USP9XGHSRGBA1L3MBTL1ALDH1A1
SCHEMBL5095089 0.73 HTR6 (0.48) ALDH1A1ELANEHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 US claimed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 US disclosed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 US disclosed
WO-2008101247-A2 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR1B, HTR1A USP9X 3887/4885GHSR 192/4885GBA1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.